Search
RenovoRx Inc
RNXTAdd to Watchlist
1.570USD
-0.060-3.68%
Market hours 09/24, 10:34（ET）
70.73MMarket Cap
LossP/E TTM
About RenovoRx Inc Company
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
RenovoRx Inc Profile
Ticker SymbolRNXT
Company nameRenovoRx Inc
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Number of employees10
Security typeOrdinary Share
Fiscal year-endAug 17
Address2570 W. El Camino Real, Ste. 320,
CityMOUNTAIN VIEW
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94040
Phone14088002649
Websitehttps://renovorx.com/
Ticker SymbolRNXT
IPO dateAug 17, 2021
CEOBagai (Shaun R)
Company Executives of RenovoRx Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Executive Chairman of the Board, Co-Founder, Chief Medical Officer
Executive Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Mr. Mark Voll
Mr. Mark Voll
Chief Financial Officer
Chief Financial Officer
260.63K
+30.70%
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
FAQs
Who are the top five shareholders of RenovoRx Inc?
The top five shareholders of RenovoRx Inc are: Mr. Mark Voll
How many institutions hold shares of RenovoRx Inc (RNXT)?
As of 2026Q1, 54 institutions hold shares of RenovoRx Inc, with a combined market value of approximately 9.02M, accounting for 20.02% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -632533.00.